Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.64 |
| ▸ | CES1 | P23141 | 2/20 | 0.64 |
| ▸ | FNTA | P49354 | 1/20 | 0.53 |
| ▸ | FNTB | P49356 | 1/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Phenylpyruvate SCHEMBL27849227 | 0.98 | CES2 (0.61) | CES2CES1FNTAFNTBAKR1B1 | |
| Methyl Phenylpyruvate SCHEMBL7622542 | 0.94 | CES2 (0.57) | CES2CES1FNTAFNTBAKR1B1 | |
| SCHEMBL10732366 | 0.89 | HTT (0.48) | CES2CES1FNTAFNTBALDH1A1 | |
| SCHEMBL10197486 | 0.89 | LMNA (0.58) | CES2CES1ALDH1A1MEN1KMT2A | |
| SCHEMBL7634176 | 0.86 | CES2 (0.52) | CES2CES1FNTAFNTBAKR1B1 | |
| Methyl Phenylpyruvate SCHEMBL29387340 | 0.84 | CES2 (0.49) | CES2CES1FNTAFNTBALDH1A1 | |
| SCHEMBL29338790 | 0.82 | CES2 (0.52) | CES2CES1FNTAFNTBAKR1B1 | |
| SCHEMBL29336973 | 0.82 | CES2 (0.52) | CES2CES1FNTAFNTBAKR1B1 | |
| SCHEMBL8870180 | 0.82 | FNTA (0.57) | FNTAFNTBALDH1A1KDM4ELMNA | |
| SCHEMBL7642353 | 0.82 | EGFR (0.49) | ALDH1A1MEN1KMT2ALMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 419 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030082101-A1 | Accelerators for increasing the rate of formation of free radicals and reactive oxygen species | CAVALIER DISCOVERY | 2003-05-01 | — | — | US | claimed |
| US-20030083380-A1 | Method of using hydroxycarboxylic acids or related compounds for treating skin changes asociated with intrinsic and extrinsic aging | YU RUEY J (US) | 2003-05-01 | — | — | US | claimed |
| WO-2002100478-A9 | ACCELERATORS FOR INCREASING THE RATE OF FORMATION OF FREE RADICALS AND REACTIVE OXYGEN SPECIES | CAVALIER DISCOVERY (US) | 2003-03-27 | — | — | WO | claimed |
| WO-2002100478-A2 | ACCELERATORS FOR INCREASING THE RATE OF FORMATION OF FREE RADICALS AND REACTIVE OXYGEN SPECIES | CAVALIER DISCOVERY (US) | 2002-12-19 | — | — | WO | claimed |
| EP-0912467-B1 | ASYMMETRIC HYDROGENATION METHOD OF A KETONIC COMPOUND AND DERIVATIVE | RHODIA CHIMIE SA (FR) | 2002-04-24 | — | — | EP | claimed |
| US-20010016604-A1 | Additives enhancing topical actions of therapeutic agents | TRISTRATA, INCORPORATED | 2001-08-23 | — | — | US | claimed |
| EP-0508324-B1 | Use of cosmetic compositions comprising 2-hydrocarboxylic acids and related compounds for alleviating signs of nail changes | YU RUEY J (US) | 1999-03-17 | — | — | EP | claimed |
| US-5834510-A | TOPICAL APPLICATION | TRISTRATA TECHNOLOGY, INC. | 1998-11-10 | — | — | US | claimed |
| US-5691378-A | Method for treating wrinkles using combinations of alpha hydroxyacids and/or alpha ketoacids | TRISTRATA TECHNOLOGY, INC. (US) | 1997-11-25 | — | — | US | claimed |
| EP-0770399-A2 | Additives enhancing topical actions of therapeutic agents | Van Scott, Eugene J., Dr. (US) | 1997-05-02 | — | — | EP | claimed |
| US-5554652-A | TOPICALLY APPLYING MIXTURE TO REDUCE OR PREVENT SKIN DISORDERS | TRISTRATA INC (US) | 1996-09-10 | — | — | US | claimed |
| US-5554654-A | COMPRISING SALICYLIC ACID, RETINOIC ACID, ERYTHROMYCIN, METRONIDAZOLE, TETRACYCLINE, CLINDAMYCIN, MINOCYCLINE, MECLOCYCLINE OR BENZILIC ACID BY COMBINING WITH 2-HYDROXY ACID, 2-KETOACID, DERIVATIVE THEREOF OR RELATED COMPOUND | TRISTRATA INC (US) | 1996-09-10 | — | — | US | claimed |
| EP-0273202-B1 | Use of hydroxycarboxylic acids to enhance therapeutic effects of topical compositions for fungal infections and pigmented spots. | SCOTT EUGENE J VAN (US) | 1995-06-21 | — | — | EP | claimed |
| EP-0599819-A2 | Additives enhancing topical actions of therapeutic agents | Van Scott, Eugene J., Dr. (US) | 1994-06-01 | — | — | EP | claimed |
| WO-1992018116-A1 | COMPOSITIONS COMPRISING 2-HYDROXYCARBOXYLIC ACIDS AND RELATED COMPOUNDS, AND METHODS FOR ALLEVIATING SIGNS OF DERMATOLOGICAL AGING | YU RUEY J (US) | 1992-10-29 | — | — | WO | claimed |
| EP-0508324-A2 | Compositions comprising 2-hydroxycarboxylic acids and related compounds, and methods for alleviating signs of dermatological aging | Yu, Ruey J., Dr. (US) | 1992-10-14 | — | — | EP | claimed |
| US-5091171-A | Skin disorders | IGI, INC. | 1992-02-25 | — | — | US | claimed |
| EP-0413528-A1 | Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use | Yu, Ruey J., Dr. (US) | 1991-02-20 | — | — | EP | claimed |
| EP-0273202-A2 | Use of hydroxycarboxylic acids to enhance therapeutic effects of topical compositions for fungal infections and pigmented spots. | Van Scott, Eugene J., Dr. (US) | 1988-07-06 | — | — | EP | claimed |
| US-4390702-A | 3-Substituted-3-fluoropyruvic acids and their esters and salts, and production thereof | DAIKAN KOGYO CO., LTD. (JP) | 1983-06-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082101-A1 | Accelerators for increasing the rate of formation of free radicals and reactive oxygen species | SOD1, SOD3, APEX1 | CES2 2804/4885CES1 3451/4885FNTA 3613/4885 |
| US-20010016604-A1 | Additives enhancing topical actions of therapeutic agents | ALOX15, PLOD3, ALOX15B | CES2 3155/4885CES1 1700/4885FNTA 3306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.